ADCT insider trading
NYSE HealthcareADC Therapeutics SA — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About ADC Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Company website: www.adctherapeutics.com
ADCT insider activity at a glance
FilingIQ has scored 74 insider transactions for ADCT since May 7, 2024. The most recent filing in our index is dated Apr 2, 2026.
Across the full history, 8 open-market purchases
and 15 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ADCT insider trades is 52.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ADCT Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for ADCT?
- FilingIQ tracks 74 Form 4 insider transactions for ADCT (ADC Therapeutics SA), covering filings from May 7, 2024 onwards. 6 of those were filed in the last 90 days.
- Are ADCT insiders net buyers or net sellers?
- Across the full Form 4 history for ADCT, 8 transactions (11%) were open-market purchases and 15 (20%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ADCT insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is ADCT in?
- ADC Therapeutics SA (ADCT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $548.78M.
Methodology & sources
Every ADCT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.